The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Vounatsos Michel since 2017.
This trader's CIK number is 1672709.
At the time of last reporting, Vounatsos Michel was the Chief Executive Officer of Biogen Inc.. (stock ticker symbol BIIB).
Also see all insider trading activities at Biogen Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2022 | BIIB | 0 | $0 | 0 | $0 | 14,907 | $0 |
| 2021 | BIIB | 0 | $0 | 0 | $0 | 16,289 | $0 |
| 2020 | BIIB | 3,100 | $748,045 | 0 | $0 | 16,841 | $0 |
| 2019 | BIIB | 4,351 | $1,007,169 | 0 | $0 | 13,648 | $0 |
| 2018 | BIIB | 780 | $250,029 | 0 | $0 | 7,041 | $0 |
| 2017 | BIIB | 2,735 | $760,856 | 0 | $0 | 1,736 | $0 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2022-02-18 | BIIB | Option Ex | 6,191 | .00 | 0 |
| 2022-02-12 | BIIB | Option Ex | 8,716 | .00 | 0 |
| 2021-02-12 | BIIB | Option Ex | 16,289 | .00 | 0 |
| 2020-11-30 | BIIB | Buy | 3,100 | 241.31 | 748,045 |
| 2020-02-15 | BIIB | Option Ex | 4,847 | .00 | 0 |
| 2020-02-12 | BIIB | Option Ex | 11,994 | .00 | 0 |
| 2019-05-02 | BIIB | Option Ex | 1,480 | .00 | 0 |
| 2019-05-01 | BIIB | Buy | 4,351 | 231.48 | 1,007,169 |
| 2019-02-15 | BIIB | Option Ex | 5,269 | .00 | 0 |
| 2019-02-12 | BIIB | Option Ex | 6,899 | .00 | 0 |
| 2018-05-02 | BIIB | Option Ex | 1,687 | .00 | 0 |
| 2018-02-15 | BIIB | Option Ex | 5,354 | .00 | 0 |
| 2017-12-29 | BIIB | Buy | 780 | 320.55 | 250,029 |
| 2017-05-02 | BIIB | Option Ex | 1,736 | .00 | 0 |
| 2017-05-01 | BIIB | Buy | 1,402 | 271.35 | 380,432 |
| 2017-02-27 | BIIB | Buy | 1,333 | 285.39 | 380,424 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Vounatsos Michel (Chief Executive Officer of Biogen Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.